Study of the Anti-EphA3 Monoclonal Antibody KB004 in Subjects With EphA3-Expressing Hematologic Malignancies

Trial Profile

Study of the Anti-EphA3 Monoclonal Antibody KB004 in Subjects With EphA3-Expressing Hematologic Malignancies

Suspended
Phase of Trial: Phase I/II

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Ifabotuzumab (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Multiple myeloma; Myelodysplastic syndromes; Myelofibrosis; Myeloproliferative disorders
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Humanigen
  • Most Recent Events

    • 07 Aug 2017 According to Humanigen media release, KaloBios Pharmaceuticals changed its name to Humanigen.
    • 16 Nov 2015 Status changed from active, no longer recruiting to suspended as reported by ClinicalTrials.gov record.
    • 13 Nov 2015 As per a KaloBios media release, company will discontinue two development programs, which consists of this and other Phase 1 trial (see profile 256869).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top